Top Page
4DMedical Ltd
(Sydney:4DX)
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
4DMedical Ltd Business Overview & Revenue Model
4DMedical Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.37M | 5.85M | 3.75M | 718.58K | 1.05M | 216.98K |
| Gross Profit | 4.05M | 5.39M | 3.52M | 684.43K | 280.62K | 125.13K |
| EBITDA | -34.14M | -45.82M | -31.86M | -33.74M | -35.25M | -18.04M |
| Net Income | -24.62M | -30.07M | -35.98M | -31.46M | -24.59M | -21.42M |
Balance Sheet | ||||||
| Total Assets | 94.81M | 94.81M | 120.02M | 92.92M | 74.31M | 92.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.88M | 6.88M | 30.61M | 69.58M | 51.11M | 80.88M |
| Total Debt | 4.31M | 4.31M | 5.12M | 5.14M | 6.24M | 1.69M |
| Total Liabilities | 30.58M | 30.58M | 49.09M | 21.46M | 14.80M | 9.28M |
| Stockholders Equity | 64.24M | 64.24M | 70.93M | 71.46M | 59.51M | 83.36M |
Cash Flow | ||||||
| Free Cash Flow | -24.37M | -34.56M | -31.17M | -23.38M | -28.35M | -15.25M |
| Operating Cash Flow | -24.31M | -34.48M | -30.87M | -22.65M | -25.27M | -14.52M |
| Investing Cash Flow | -1.62M | -1.62M | -40.04M | -1.61M | -3.50M | -580.45K |
| Financing Cash Flow | 12.37M | 12.37M | 31.94M | 42.73M | -995.47K | 87.55M |
4DMedical Ltd Technical Analysis
4DMedical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.84B | -49.51 | -44.49% | ― | 55.91% | 22.60% | |
50 Neutral | AU$105.58M | -7.86 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$241.52M | -145.83 | -2.01% | ― | 16.93% | 76.47% | |
48 Neutral | AU$71.31M | -3.04 | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$165.43M | -15.52 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$58.77M | -3.89 | -128.19% | ― | -14.25% | -22.83% |
4DMedical Ltd Corporate Events
4DMedical Limited has announced a significant expansion of its distribution agreement with Philips, which will now include the CT:VQ™ technology in its North American product catalogue. This deal, valued at approximately US$10 million over two years, marks a major commercial milestone for 4DMedical, as it leverages Philips’ extensive network to distribute its innovative imaging solution across the United States and Canada. The CT:VQ™ technology offers a superior alternative to traditional nuclear VQ imaging by eliminating the need for radiotracers, thereby streamlining patient access and improving diagnostic capabilities. With over one million nuclear VQ scans performed annually in the U.S., 4DMedical is poised to capture a significant portion of this market, potentially displacing traditional methods entirely.
4DMedical Limited announced the expiry of its listed options, exercisable at $1.365, on 31 December 2025. The official quotation of these options will cease on 23 December 2025. This announcement is significant for stakeholders as it provides a deadline for exercising options, potentially impacting investor decisions and the company’s financial strategy.
4DMedical Ltd has announced the quotation of 53,333 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of the company’s ongoing efforts to expand its market presence and enhance its financial flexibility, potentially impacting its operational capabilities and stakeholder interests positively.
4DMedical Ltd announced the quotation of additional securities on the Australian Securities Exchange, with a total of 189,818 ordinary fully paid securities to be quoted. This move reflects the company’s ongoing efforts to strengthen its financial position and potentially expand its market presence, signaling positive implications for stakeholders and investors.
4DMedical Ltd addressed a query from the ASX regarding the impairment assessment of its intangible assets, following its acquisition of Imbio Inc. The company outlined its assumptions and evidence provided to auditors, emphasizing its commitment to achieving forecasted revenue growth through commercial activities and partnerships. The company aims to secure an unqualified audit opinion in future financial statements by enhancing its revenue generation strategies.
4DMedical Limited announced the successful passage of all resolutions at its Annual General Meeting, reflecting strong shareholder support. The resolutions included re-elections of directors and the issuance of options and restricted stock units to key personnel, indicating a strategic focus on leadership stability and incentivization. This outcome supports 4DMedical’s ongoing efforts to enhance its market position and operational capabilities in the medical imaging industry.
4DMedical Limited has achieved a major milestone with the FDA clearance of its CT:VQ™ technology, the first non-contrast, CT-based ventilation-perfusion imaging solution. This approval, coupled with immediate reimbursement confirmation from CMS, positions CT:VQ™ to potentially replace traditional nuclear VQ imaging, tapping into a billion-dollar market. The company has rapidly expanded its commercial footprint, with Stanford University adopting the technology and partnerships with AstraZeneca in Brazil and key contracts in Australia. These developments, alongside strong financial performance and strategic partnerships, underscore 4DMedical’s growing influence in the respiratory imaging sector.
4DMedical Limited presented its achievements and future plans at the 2025 Annual General Meeting, highlighting a 95% increase in SaaS revenue and the successful launch of the CT:VQ solution, which received FDA clearance and its first commercial contract. The company reported a total income of $16.5 million for FY25 and maintained a strong cash balance of $33.5 million. With strategic investments in U.S. market initiatives and global industry conferences, 4DMedical is poised to capitalize on a large global market opportunity, particularly with its CT:VQ solution, which aims to improve patient care by reducing costs and enhancing access.
4DMedical Limited announced the withdrawal of Resolution 8 from its upcoming Annual General Meeting agenda due to the ASX not granting a waiver from Listing Rule 7.5.4. This resolution involved ratifying a prior agreement to issue shares to Pro Medicus Limited. The withdrawal will not affect the validity of proxy forms already submitted for other resolutions at the AGM. This decision reflects the company’s adherence to regulatory requirements and may impact its strategic financial arrangements.
4DMedical Ltd announced the quotation of 492,109 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move reflects the company’s ongoing efforts to enhance its financial flexibility and support its growth strategy, potentially impacting its market position and offering new opportunities for stakeholders.
4DMedical Limited has announced the commercial rollout of its CT:VQ™ technology at Stanford University, marking the first U.S. Academic Medical Centre to adopt the FDA-cleared technology. This move is part of a broader strategy to establish CT:VQ™ as a new standard of care in pulmonary imaging across leading U.S. institutions. Additionally, 4DMedical, in partnership with AstraZeneca, is expanding its Lung Health Screening Program in Brazil to five more hospitals, significantly increasing the program’s reach and impact. These developments are expected to accelerate clinical adoption and generate real-world evidence, positioning 4DMedical as a leader in respiratory imaging technology.
4DMedical Ltd has announced the quotation of 377,371 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s ongoing efforts to leverage financial instruments for growth and expansion, potentially impacting its market position and offering new opportunities for stakeholders.
4DMedical Limited has issued 1,356,416 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. This move, disclosed without the need for a prospectus under the Corporations Act, indicates the company’s compliance with relevant regulations and supports its strategic growth initiatives.
4DMedical Ltd has announced the quotation of 1,356,416 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move, resulting from the exercise of options or conversion of other securities, is expected to bolster the company’s financial standing and potentially enhance its market position.
4DMedical Ltd has announced the quotation of 2,404,728 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from October 9, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its stakeholders, potentially strengthening its position in the medical technology sector.
4DMedical Ltd announced the issuance of unquoted securities, including 679,085 performance rights and 2,711,738 options, as part of an employee incentive scheme. This move is likely to impact the company’s operational strategy by aligning employee interests with company performance, potentially enhancing its market position and stakeholder value.
4DMedical Limited has successfully raised $22.6 million through the exercise of deep in-the-money options, significantly boosting its cash reserves to $45.5 million. This financial influx, alongside strategic investments and tax incentives, will support the company’s strategic priorities, including the commercialization of its CT:VQ™ solution and expansion into the U.S. healthcare market. The company is also poised for further capital inflows with additional options set to expire in December 2025, potentially adding $30.2 million to its balance sheet. These developments underscore 4DMedical’s commitment to advancing its market position and enhancing its product offerings in the respiratory imaging industry.
4DMedical Ltd has announced the quotation of 365,338 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 2, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market position and providing value to its stakeholders.
4DMedical Ltd has announced the issuance of piggyback options following the exercise of previously listed options, with a total of 1,065,402 securities set to be quoted. This move is part of the company’s strategic efforts to strengthen its market position and potentially increase its capital base, which could have significant implications for its stakeholders and future growth opportunities.
4DMedical Ltd has announced the application for the quotation of new securities on the ASX, following the conversion of options or other convertible securities. This move is part of the company’s ongoing efforts to strengthen its financial position and expand its market presence, potentially impacting its operational capabilities and stakeholder interests positively.
4DMedical Ltd has announced the quotation of new securities on the Australian Securities Exchange (ASX), specifically piggyback options issued upon the exercise of previously listed options. This move, involving over 3 million securities, is part of the company’s strategic financial operations to enhance its market positioning and provide value to its stakeholders.
4DMedical Ltd has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The securities, which have been issued as a result of options being exercised or convertible securities being converted, are part of the company’s strategic financial maneuvers. This move is expected to enhance the company’s market presence and provide additional capital to support its ongoing operations and growth initiatives.
4DMedical Limited has announced its Annual General Meeting scheduled for 30 October 2025, where shareholders will review the company’s FY25 performance and vote on various business items, including the re-election of directors and the issuance of securities. This meeting is a significant event for stakeholders as it will provide insights into the company’s strategic direction and financial health, potentially impacting its market positioning and investor confidence.
4DMedical Limited has released its 2025 Corporate Governance Statement, detailing its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes its commitment to transparency and accountability by outlining its governance framework, which includes policies on anti-bribery, risk management, and diversity. This announcement reinforces 4DMedical’s dedication to maintaining high standards of corporate governance, which is crucial for its stakeholders, including shareholders, employees, and the community.
4DMedical’s Annual Report for 2025 highlights its continued efforts in revolutionizing lung imaging technology, particularly through its CT:VQ™ product. The report outlines strategic growth, commercial partnerships, and clinical research initiatives, positioning the company as a leader in the cardiopulmonary imaging sector and indicating a strong outlook for FY26.
4DMedical Ltd has announced the quotation of 56,250 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, following the exercise of options or conversion of other convertible securities. This move is expected to enhance the company’s liquidity and potentially attract more investors, reinforcing its position in the medical imaging sector.
4DMedical Ltd has announced the quotation of new securities on the ASX, specifically piggyback options issued upon the exercise of previously listed options. This development involves the issuance of 2,872,980 options set to expire on September 1, 2027. The move is part of the company’s strategic financial operations, potentially impacting its market presence and offering stakeholders an opportunity for investment growth.
4DMedical Ltd has announced the quotation of 2,872,980 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective September 25, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide additional value to its stakeholders by expanding its financial resources.
4DMedical Ltd has announced the issuance of new securities, specifically piggyback options, following the exercise of previously listed options. This move, involving the quotation of over 3.5 million securities, is part of the company’s strategic financial maneuvers to enhance its market position and operational capabilities.
4DMedical Ltd announced the issuance of 3,580,890 new fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of the company’s strategy to strengthen its financial position and support its growth initiatives in the medical imaging sector.
4DMedical Ltd has announced the quotation of new securities, specifically piggyback options, on the Australian Securities Exchange (ASX). The issuance of these options, expiring on September 1, 2027, reflects the company’s ongoing efforts to strengthen its financial position and enhance shareholder value. This strategic move may impact the company’s market presence and offer potential benefits to stakeholders by providing additional investment opportunities.
4DMedical Ltd has announced the quotation of 2,913,928 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, effective from September 18, 2025. This move is part of the company’s strategy to leverage convertible securities, potentially enhancing its market presence and providing additional capital to support its operations and growth initiatives.
4DMedical Ltd has announced the quotation of new securities on the Australian Securities Exchange (ASX), specifically piggyback options issued upon the exercise of previously listed options. This move is part of the company’s strategic financial maneuvers to bolster its market position and potentially increase its capital base, which could have significant implications for its operational capabilities and stakeholder interests.
4DMedical Ltd has announced the quotation of 4,166,698 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of the company’s strategic efforts to leverage convertible securities, potentially enhancing its financial flexibility and market presence.
4DMedical Limited is hosting an exclusive webinar featuring Dr. Kyle Hogarth, a renowned pulmonologist, to discuss the clinical applications and benefits of 4DMedical’s respiratory imaging technology. This session aims to provide shareholders with insights into the company’s innovative products and their impact on lung care, highlighting the advantages over traditional diagnostic methods and the future of respiratory imaging.
4DMedical Limited announced an update to its Top 20 Option Holders list and Distribution Schedule, correcting an error related to the expiry date of its Piggyback Options, now set to expire on 1 September 2027. This update ensures accurate information for stakeholders and maintains transparency in the company’s option holdings, which is crucial for investor confidence and market operations.
4DMedical Limited has announced a collaboration with AstraZeneca in Brazil and a new contract with Spectrum Medical Imaging, marking its first involvement in Australia’s National Lung Cancer Screening Program. While the Spectrum contract is not immediately significant in terms of revenue, it is expected to grow over time, highlighting 4DMedical’s strategic expansion and potential impact on lung health management.
4DMedical Ltd has released its Top 20 Investors Report, detailing the major stakeholders in the company as of September 11, 2025. The report highlights Citicorp Nominees Pty Limited as the largest investor, holding 24.41% of the issued capital. This information provides insight into the company’s shareholder structure, which is crucial for understanding its market positioning and potential influence on strategic decisions.
4DMedical Ltd has announced the application for the quotation of its unlisted Piggyback options under the ASX Listing Rule 2.5, condition 6. This move involves the issuance of 23,470,090 options set to expire on September 1, 2027, reflecting the company’s strategic efforts to enhance its financial instruments and market presence.
4DMedical Ltd announced the issuance of 7,179,233 unquoted equity securities, specifically options expiring on February 29, 2028, with an exercise price of $0.75. This move is part of the company’s strategic financial operations, potentially impacting its market positioning by enhancing its capital structure and providing opportunities for future growth and investment.
4DMedical Ltd announced the quotation of 7,179,233 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and potentially increase its capital base, which could have implications for its operational expansion and stakeholder interests.
4DMedical Limited has issued 339,255 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. This issuance was completed without disclosure to investors under specific provisions of the Corporations Act, and the company has ensured compliance with relevant legislative requirements, indicating a strategic move to strengthen its financial position and incentivize long-term growth.
4DMedical Ltd has announced the quotation of additional securities on the Australian Securities Exchange (ASX), with a total of 349,255 ordinary fully paid shares being issued. This move is part of the company’s ongoing efforts to enhance its capital structure and support its growth initiatives, potentially impacting its market positioning and providing opportunities for stakeholders.
4DMedical Ltd has announced the issuance of unquoted equity securities, which includes performance rights and options under an employee incentive scheme. This move is part of the company’s strategy to incentivize its workforce and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and market positioning.
4DMedical Ltd announced the issuance of 12,964,580 unquoted equity securities, specifically options expiring on February 29, 2028, with an exercise price of $0.75. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing capital for future projects, affecting stakeholders’ interests.
4DMedical Limited has announced agreements with a leading global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy its lung health analysis software. These agreements, effective until 2027, aim to enhance lung cancer screening and lung health assessments in Brazil and Australia, including support for the National Lung Cancer Screening Program. The collaboration with Spectrum Medical Imaging will integrate 4DMedical’s advanced analytical tools into existing imaging infrastructure, enhancing the quality and depth of lung health diagnostics.